Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

To explore changes in body weight and cardiometabolic risk factors after treatment withdrawal in the STEP 1 trial extension.

[1]  F. Greenway,et al.  Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. , 2021, JAMA.

[2]  T. Wadden,et al.  Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial , 2021, The Lancet.

[3]  T. Wadden,et al.  Once-Weekly Semaglutide in Adults with Overweight or Obesity. , 2021, The New England journal of medicine.

[4]  J. Halford,et al.  Mechanisms of weight regain. , 2021, European journal of internal medicine.

[5]  Sathish Kumar Jayapal,et al.  Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 , 2020, Journal of the American College of Cardiology.

[6]  T. Wadden,et al.  Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5 , 2020, Obesity.

[7]  Medicines And Healthcare Products Regulatory Agency , 2020, Definitions.

[8]  J. Després,et al.  Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management. , 2018, Circulation.

[9]  D. Bessesen,et al.  Progress and challenges in anti-obesity pharmacotherapy. , 2017, The lancet. Diabetes & endocrinology.

[10]  2. Classification and Diagnosis of Diabetes , 2016, Diabetes Care.

[11]  R. Plodkowski,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. , 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[12]  T. Wadden,et al.  Association of Weight Loss Maintenance and Weight Regain on 4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial , 2016, Diabetes Care.

[13]  Luca Busetto,et al.  European Guidelines for Obesity Management in Adults , 2015, Obesity Facts.

[14]  F. Greenway.  Physiological adaptations to weight loss and factors favouring weight regain , 2015, International Journal of Obesity.

[15]  C. Apovian,et al.  Pharmacological management of obesity: an endocrine Society clinical practice guideline. , 2015, The Journal of clinical endocrinology and metabolism.

[16]  Obesity Expert Panel.  Expert panel report: Guidelines (2013) for the management of overweight and obesity in adults , 2014, Obesity.

[17]  S. Yanovski,et al.  Long-term drug treatment for obesity: a systematic and clinical review. , 2014, JAMA.

[18]  A. Shulkes,et al.  Long-term persistence of hormonal adaptations to weight loss. , 2011, The New England journal of medicine.

[19]  N. Weissman,et al.  Multicenter, placebo-controlled trial of lorcaserin for weight management. , 2010, The New England journal of medicine.

[20]  Wei Zhang,et al.  The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis , 2009, BMC public health.

[21]  Deborah F Tate,et al.  Maintaining large weight losses: the role of behavioral and psychological factors. , 2008, Journal of consulting and clinical psychology.

[22]  Alain Golay,et al.  Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients , 1998, The Lancet.

[23]  A. Rissanen,et al.  Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. , 1998, Lancet.